About Us
About Us
Story
Edgene is Biotech company developing
a first-in-class gene therapeutics for
mitochondrial diseases cause by mutations of
mitochondrial genome.
Mitochondrial diseases are caused by genetic mutations resulting defects in mitochondria which are energy factories found in side almost all the cells in the body, but no cure and very limited or no treatment options are available now. Edgene is advancing the mitochondrial gene editing platforms developed by Dr. Jin-Soo Kim, our Founder, and developing gene therapeutics for patients with mitochondrial diseases.
To accelerating development and clinical application, Edgene’s scientists are collaborating with international leading companies, institutes and clinical centers in mitochondrial diseases and gene editing technologies.
Leaderships
Founder and CTO of Edgene
(2022 – Present)
Jin-Soo Kim, Ph.D.
- 2022- Present, CTO, Edgene, Inc.
- 2014-2022, Director, Center for Genome Engineering, Institute for Basic Science
- 2005-2016, Professor, Department of Chemistry, Seoul National University
- 1997-1999, Principal Investigator, Samsung Biomedical Research Institute
- 1994-1997, Research Associate, MIT/HHMI, MA, USA
- University of Wisconsin-Madison, Ph.D., WI USA
- Seoul National University, B.S./M.S., South Korea
CEO of Edgene
(2023 – Present)
Paul Youngho Kim, Ph.D.
Committee Member of Korea Drug Development Fund, Former CEO of ToolGen, Inc.
- 2023- Present, CEO, Edgene, Inc.
- 2020-2023, CEO/Chairman, Toolgen, Inc.
- 2018-2020, CEO/Chairman/Advisor, Medifron_DBT Co. Ltd
- 2017-2019, Director, Korea Biotechnology Industry Organization
- 2012-2018, CEO/CTO, Medifron_DBT Co. Ltd
- 2002-2012, Director/CSO at Digitalbiotech Co. Ltd
- 2001-2002, Senior Research Scientist, Toolgen, Inc.
- 1996-2001, Research Fellow, Lab. of Molecular Cardiology, NHLBI, NIH, USA
- Seoul National University, B.S./M.S./Ph.D., South Korea
Partners
Copyright @ EDGENE. All Right Reserved
Privacy policy